Cullgen (Shanghai) divulges new PROTACs for cancer
May 9, 2023
Cullgen (Shanghai) Inc. has patented proteolysis targeting chimera (PROTAC) compounds comprising a DDB1 binding moiety covalently bonded to a target protein binding moiety through a linker. They are reported to be useful for the treatment of cancer.
ガンバさん 2023年5月10日 17:12
Cullgen (Shanghai) divulges new PROTACs for cancer
May 9, 2023
Cullgen (Shanghai) Inc. has patented proteolysis targeting chimera (PROTAC) compounds comprising a DDB1 binding moiety covalently bonded to a target protein binding moiety through a linker. They are reported to be useful for the treatment of cancer.